文献(301～400)

301. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;

357: 2248-2261. PMID: 17984166

302. Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-

HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239. PMID: 18757089

303. Takano H, Mizuma H, Kuwabara Y, et al. PEARL Study Investigators. Effects of pitavastatin in Japanese patients with chronic heart

failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-925. PMID: 23502990

304. Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and

Heart Failure: A Meta-Analysis. JACC Heart Fail 2016; 4: 870-880. PMID: 27614940

305. Massie BM, Collins JF, Ammon SE, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients

with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-

1624. PMID: 19289640

306. Homma S, Thompson JL, Pullicino PM, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus

rhythm. N Engl J Med 2012; 366: 1859-1869. PMID: 22551105

307. Davis BR, Cutler JA, Furberg CD, et al. ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens

and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further

analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137: 313-320.

PMID: 12204014

308. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce

decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 935-944. PMID: 25286913

309. Buggey J, Mentz RJ, Pitt B, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 2015; 169: 323-333.

PMID: 25728721

310. Imamura T, Kinugawa K. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection

Fraction as Well as in Those With Reduced Ejection Fraction. Int Heart J 2016; 57: 600-606. PMID: 27581675

311. Cleland JG, Tendera M, Adamus J, et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF)

study. Eur Heart J 2006; 27: 2338-2345. PMID: 16963472

312. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart

failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. PMID: 13678871

313. Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investiga tors. Irbesartan in patients with heart failure and preserved ejection

fraction. N Engl J Med 2008; 359: 2456-2467. PMID: 19001508

314. Yamamoto K, Origasa H, Hori M, et al. J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the

Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118. PMID: 22983988

315. Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl

J Med 2014; 370: 1383-1392. PMID: 24716680

316. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation

group trial. Circulation 2006; 114: 397-403. PMID: 16864724

317. Lund LH, Benson L, Dahlström U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with

heart failure and preserved ejection fraction. JAMA 2012; 308: 2108- 2117. PMID: 23188027

318. Liu F, Chen Y, Feng X, et al. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One 2014; 9:

e90555. PMID: 24599093

319. Lund LH, Benson L, Dahlström U, et al. Association between use of β-blockers and outcomes in patients with heart failure and preserved

ejection fraction. JAMA 2014; 312: 2008-2018. PMID: 25399276

320. Redfield MM, Anstrom KJ, Levine JA, et al. NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure

with Preserved Ejection Fraction. N Engl J Med 2015; 373: 2314- 2324. PMID: 26549714

321. Lim SL, Benson L, Dahlström U, et al. Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved

Ejection Fraction. Circ Heart Fail 2017; 10: e003534. PMID: 28377439

322. Dobre D, van Veldhuisen DJ, DeJongste MJ, et al. Prescription of beta- blockers in patients with advanced heart failure and preserved left

ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007; 9: 280-286. PMID: 17027334

323. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients

&gt;or=65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 2008; 101: 217-222. PMID:

18178410

324. El-Refai M, Peterson EL, Wells K, et al. Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction

versus those with reduced ejection fraction. J Card Fail 2013; 19: 73- 79. PMID: 23384631

325. Takada T, Sakata Y, Miyata S, et al. CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure

with reduced and preserved ejection fraction: a report from the CHART-2 Study. Eur J Heart Fail 2014; 16: 309-316. PMID: 24464774

326. Mitchell LB. Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. Curr Opin Cardiol 1997; 12:

33-40. PMID: 9132079

327. Aiba T, Yamagata K, Shimizu W, et al. Electrophysiologic study-guided amiodarone for sustained ventricular tachyarrhythmias associated

with structural heart diseases. Circ J 2008; 72: 88-93. PMID: 18159106

328. Mirowski M, Reid PR, Winkle RA, et al. Mortality in patients with implanted automatic defibrillators. Ann Intern Med 1983; 98: 585-

588. PMID: 6846971

329. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term

outcome. N Engl J Med 1988; 318: 19-24. PMID: 3336381

330. Kim YH, Sosa-Suarez G, Trouton TG, et al. Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with

ischemic heart disease. Circulation 1994; 89: 1094-1102. PMID: 8124795

331. Gonska BD, Cao K, Schaumann A, et al. Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: results

and long-term follow-up. J Am Coll Cardiol 1994; 24: 1506-1514. PMID: 7930283

332. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in

patients with coronary artery disease and an implantable cardioverter- defibrillator. Circulation 1997; 96: 1525-1531. PMID: 9315542

333. Anderson J. Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an

antagonist’s

viewpoint. Prog Cardiovasc Dis 1996; 38: 393-400. PMID: 8604444

334. Saksena S, Madan N, Lewis C. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular

tachyarrhythmias. Prog Cardiovasc Dis 1996; 38: 445-454. PMID: 8638025

335. Kim SG. Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators.

Am Heart J 1995; 130: 1144-1150. PMID: 7484752

336. Böcker D, Block M, Borggrefe M, et al. Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.

Eur Heart J 1997; 18: 26-30. PMID: 9049512

337. Zipes DP. Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation

1995; 91: 2115-2117. PMID: 7697837

338. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter- defibrillator. Circulation 1994; 89: 1851-1858. PMID:

8149550

339. Cox JL. Patient selection criteria and results of surgery for refractory ischemic ventricular tachycardia. Circulation 1989; 79: I163-I177.

PMID: 2655975

340. Thomas AC, Moser SA, Smutka ML, et al. Implantable defibrillation: eight years clinical experience. Pacing Clin Electrophysiol 1988; 11:

2053-2058. PMID: 2463587

341. Satomi K, Kurita T, Suyama K, et al. Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic

right ventricular dysplasia. J Cardiovasc Electrophysiol 2006; 17: 469-476. PMID: 16684016

342. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable

defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583. PMID: 9411221

343. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients

resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754. PMID: 10942742

344. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter

defibrillator against amiodarone. Circulation 2000; 101: 1297-1302. PMID: 10725290

345. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials.

AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable

Defibrillator Study. Eur Heart J 2000; 21: 2071-2078. PMID: 11102258

346. Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/ HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable

cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate

use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society

of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and

Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013; 61: 1318-1368. PMID: 23453819

347. Zipes DP, Camm AJ, Borggrefe M, et al. European Heart Rhythm Association. ACC/AHA/ESC 2006 guidelines for management of patients

with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American

Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop

Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll

Cardiol 2006; 48: e247-e346. PMID: 16949478

348. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy:

a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-2879. PMID: 15598919

349. Kuck KH, Schaumann A, Eckardt L, et al. VTACH study group.Catheter ablation of stable ventricular tachycardia before defibrillator

implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375: 31-40.

PMID: 20109864

350. Moss AJ, Hall WJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an

implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940.

PMID: 8960472

351. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a

defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883. PMID: 11907286

352. Buxton AE, Lee KL, Fisher JD, et al. Multicenter Unsustained Tachycardia

Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med

1999; 341: 1882-1890. PMID: 10601507

353. Hohnloser SH, Kuck KH, Dorian P, et al. DINAMIT Investigators.

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.

PMID: 15590950

354. Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.

Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158. PMID:

15152060

355. Goldenberg I, Gillespie J, Moss AJ, et al. Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II. Long-term

benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic

Defibrillator Implantation Trial II. Circulation 2010; 122: 1265-1271. PMID: 20837894

356. Shiga T, Hagiwara N, Ogawa H, et al. Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators. Sudden cardiac

death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary

intervention era: results from the HIJAMI-II registry. Heart 2009; 95: 216-220. PMID: 18728065

357. Tanno K, Miyoshi F, Watanabe N, et al. MADIT II. The Multicenter

Automtic Defibrillator Implantation Trial. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J 2005;

69: 19-22. PMID: 15635196

358. Satake H, Fukuda K, Sakata Y, et al. CHART-2 Investigators. Current status of primary prevention of sudden cardiac death with implantable

cardioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J 2015; 79: 381-390. PMID:

25476195

359. Greenberg H, Case RB, Moss AJ, et al. MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator

Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43: 1459-1465. PMID: 15093884

360. Køber L, Thune JJ, Nielsen JC, et al. DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart

Failure. N Engl J Med 2016; 375: 1221-1230. PMID: 27571011

361. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy

Trial (CAT). Circulation 2002; 105: 1453-1458. PMID:11914254

362. Strickberger SA, Hummel JD, Bartlett TG, et al. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-

defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--

AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-1712. PMID: 12767651

363. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION)

Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J

Med 2004; 350: 2140-2150. PMID: 15152059

364. Shiba N, Shimokawa H. Chronic heart failure in Japan: implications of the CHART studies. Vasc Health Risk Manag 2008; 4: 103-113.

PMID: 18629369

365. 日本不整脈学会WCD ワーキングループ．着用型自動除細動器(WCD) の臨床使用に関するステートメント（2015年4月改訂）．

http://new.jhrs.or.jp/pdf/guideline/statement201505_01.pdf

366. Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.

Heart Lung Transplant 2015; 34: 1305-1309. PMID: 26094085

367. Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular

dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6: 117-128. PMID: 23275233

368. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates,

compliance, and survival. J Am Coll Cardiol 2010; 56: 194-203.PMID: 20620738

369. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm

Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing

Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices)

developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol

2008; 51: e1-62. PMID: 18498951

370. Baldasseroni S, Opasich C, Gorini M, et al. Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is

associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian

network on congestive heart failure. Am Heart J 2002; 143: 398-405. PMID: 11868043

371. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994; 17: 1974-1979.

PMID: 7845801

372. Bakker PF, Meijburg HW, de Vries JW, et al. Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular

function. J Interv Card Electrophysiol 2000; 4: 395-404. PMID: 10936005

373. Cazeau S, Leclercq C, Lavergne T, et al. Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite

biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880. PMID:

11259720

374. Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med

2002; 346: 1845-1853. PMID: 12063368

375. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients

with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780- 1787. PMID: 12419298

376. Auricchio A, Stellbrink C, Sack S, et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect

of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am

Coll Cardiol 2002; 39: 2026-2033. PMID: 12084604

377. Young JB, Abraham WT, Smith AL, et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators.

Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE

ICD Trial. JAMA 2003; 289: 2685-2694. PMID: 12771115

378. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular

conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454-1459. PMID: 14563591

379. Abraham WT, Young JB, León AR, et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease

progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly

symptomatic chronic heart failure. Circulation 2004; 110: 2864-2868. PMID: 15505095

380. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac

resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549. PMID: 15753115

381. Salukhe TV, Dimopoulos K, Francis D. Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary

COMPANION data with CONTAK-CD, InSync ICD, MIRACLE and MUSTIC. Int J Cardiol 2004; 93: 101-103. PMID: 14975534

382. Aranda JM, Conti JB, Johnson JW, et al. Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities

other than left bundle-branch block: analysis of the Multicenter In- Sync Randomized Clinical Evaluation (MIRACLE). Clin Cardiol

2004; 27: 678-682. PMID: 15628109

383. Egoavil CA, Ho RT, Greenspon AJ, et al. Cardiac resynchronization therapy in patients with right bundle branch block: analysis of pooled

data from the MIRACLE and Contak CD trials. Heart Rhythm 2005; 2: 611-615. PMID: 15922268

384. Wilkoff BL, Cook JR, Epstein AE, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or

ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID)

Trial. JAMA 2002; 288: 3115-3123. PMID: 12495391

385. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. MOde Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure

and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.

Circulation 2003; 107: 2932-2937. PMID: 12782566

386. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently

paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol 2007; 30: S23-S30. PMID: 17302711

387. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular

Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;

368: 1585-1593. PMID: 23614585

388. Buxton AE, Lee KL, DiCarlo L, et al. Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify

patients with coronary artery disease who are at risk for sudden death. N Engl J Med 2000; 342: 1937-1945. PMID: 10874061

389. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the

CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928-1932. PMID: 16782715

390. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of

death: a meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688. PMID: 16966347

391. Auricchio A, Metra M, Gasparini M, et al. Multicenter Longitudinal Observational Study (MILOS) Group. Long-term survival of patients

with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 2007; 99: 232-238.

PMID: 17223424

392. Wilkoff BL, Fauchier L, Stiles MK, et al. Document Reviewers. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on

optimal implantable cardioverter-defibrillator programming and testing. Europace 2016; 18: 159-183. PMID: 26585598

393. Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-

analysis of randomized controlled trials. Am Heart J 2012; 163: 260-267.e3. PMID: 22305845

394. Jeevanantham V, Zareba W, Navaneethan S, et al. Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients

with narrow QRS complex. Cardiol J 2008; 15: 230-236. PMID:18651415

395. Cazeau SJ, Daubert JC, Tavazzi L, et al. Responders to cardiac resynchronization therapy with narrow or intermediate QRS complexes

identified by simple echocardiographic indices of dyssynchrony: the DESIRE study. Eur J Heart Fail 2008; 10: 273-280. PMID:

18314381

396. Beshai JF, Grimm RA, Nagueh SF, et al. RethinQ Study Investigators. Cardiac-resynchronization therapy in heart failure with narrow

QRS complexes. N Engl J Med 2007; 357: 2461-2471. PMID:17986493

397. Ruschitzka F, Abraham WT, Singh JP, et al. EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS

complex. N Engl J Med 2013; 369: 1395-1405. PMID: 23998714

398. Linde C, Abraham WT, Gold MR, et al. REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study

Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with

left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834-1843. PMID: 19038680

399. Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of

heart-failure events. N Engl J Med 2009; 361: 1329-1338. PMID: 19723701

400. Tang AS, Wells GA, Talajic M, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-

resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2395. PMID: 21073365